SARS Antibody Testing in Children: Development of Oral Fluid Assays for IgG Measurements.
COVID-19
antibody
children
oral fluid
schools
surveys
Journal
Microbiology spectrum
ISSN: 2165-0497
Titre abrégé: Microbiol Spectr
Pays: United States
ID NLM: 101634614
Informations de publication
Date de publication:
23 02 2022
23 02 2022
Historique:
pubmed:
6
1
2022
medline:
22
3
2022
entrez:
5
1
2022
Statut:
ppublish
Résumé
Seroepidemiological studies to monitor antibody kinetics are important for assessing the extent and spread of SARS-CoV-2 in a population. Noninvasive sampling methods are advantageous for reducing the need for venipuncture, which may be a barrier to investigations, particularly in pediatric populations. Oral fluids are obtained by gingiva-crevicular sampling from children and adults and are very well accepted. Enzyme immunoassays (EIAs) based on these samples have acceptable sensitivity and specificity compared to conventional serum-based antibody EIAs and are suitable for population-based surveillance. We describe the development and evaluation of SARS-CoV-2 IgG EIAs using SARS-CoV-2 viral nucleoprotein (NP) and spike (S) proteins in IgG isotype capture format and an indirect receptor-binding-domain (RBD) IgG EIA, intended for use in children as a primary endpoint. All three assays were assessed using a panel of 1,999 paired serum and oral fluids from children and adults participating in school SARS-CoV-2 surveillance studies during and after the first and second pandemic wave in the United Kingdom. The anti-NP IgG capture assay was the best candidate, with an overall sensitivity of 75% (95% confidence interval [CI]: 71 to 79%) and specificity of 99% (95% CI: 78 to 99%) compared with paired serum antibodies. Sensitivity observed in children (80%, 95% CI: 71 to 88%) was higher than that in adults (67%, CI: 60% to 74%). Oral fluid assays (OF) using spike protein and RBD antigens were also 99% specific and achieved reasonable but lower sensitivity in the target population (78%, 95% CI [68% to 86%] and 53%, 95% CI [43% to 64%], respectively).
Identifiants
pubmed: 34985331
doi: 10.1128/spectrum.00786-21
pmc: PMC8729769
doi:
Substances chimiques
Antibodies, Viral
0
Immunoglobulin G
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0078621Subventions
Organisme : Department of Health
Pays : United Kingdom
Références
Eur Respir J. 2020 Aug 27;56(2):
pubmed: 32398307
Clin Diagn Virol. 1994 Aug;2(4-5):231-43
pubmed: 15566769
Lancet Child Adolesc Health. 2021 Jun;5(6):417-427
pubmed: 33740430
Mod Pathol. 2020 Nov;33(11):2156-2168
pubmed: 32879413
BMJ Open. 2021 Mar 30;11(3):e048391
pubmed: 33785495
Epidemiol Infect. 1988 Oct;101(2):197-201
pubmed: 3141201
JCI Insight. 2020 Sep 17;5(18):
pubmed: 32796155
EClinicalMedicine. 2021 Nov;41:101150
pubmed: 34608455
J Clin Microbiol. 2020 Dec 17;59(1):
pubmed: 33067270
Cell. 2021 Apr 1;184(7):1858-1864.e10
pubmed: 33631096
J Med Virol. 1993 Jul;40(3):235-40
pubmed: 8355022
J Immunol Methods. 2002 Aug 1;266(1-2):111-6
pubmed: 12133627
J Infect. 2021 May;82(5):162-169
pubmed: 33766553
Emerg Infect Dis. 2010 Oct;16(10):1532-8
pubmed: 20875277
Am J Med. 1997 Apr 1;102(4A):21-5
pubmed: 9217635
Paediatr Respir Rev. 2020 Sep;35:9-14
pubmed: 32593648
Heliyon. 2020 Sep;6(9):e04943
pubmed: 32954038
Vaccines (Basel). 2015 Dec 09;3(4):988-1003
pubmed: 26690230
Lancet Infect Dis. 2021 Mar;21(3):344-353
pubmed: 33306981
J Virol Methods. 2003 Dec;114(2):151-8
pubmed: 14625050
J Allergy Clin Immunol. 2021 Feb;147(2):545-557.e9
pubmed: 33221383
Emerg Infect Dis. 2021 Jul;27(7):1795-1801
pubmed: 34152947
Am J Epidemiol. 2004 Apr 15;159(8):786-94
pubmed: 15051588
Epidemiol Rev. 2002;24(2):125-36
pubmed: 12762088
J Clin Microbiol. 2021 Apr 20;59(5):
pubmed: 33318065
Microbiol Spectr. 2021 Oct 31;9(2):e0073121
pubmed: 34523985
Vaccine. 2020 Mar 10;38(12):2660-2670
pubmed: 32070679
AIDS Patient Care STDS. 2009 Jul;23(7):571-6
pubmed: 19530953
Infection. 2022 Apr;50(2):439-446
pubmed: 34562263
Lancet. 2021 Jan 16;397(10270):220-232
pubmed: 33428867
J Egypt Public Health Assoc. 1991;66(1-2):123-34
pubmed: 1800614
AIDS Patient Care STDS. 2007 Sep;21(9):621-37
pubmed: 17919089
Public Health. 2001 May;115(3):201-7
pubmed: 11429716
Lancet. 1987 Jul 11;2(8550):72-5
pubmed: 2885575
J Clin Microbiol. 2021 Jan 21;59(2):
pubmed: 33234589
Sci Immunol. 2020 Oct 8;5(52):
pubmed: 33033173